Literatur

AUA Practice Guidelines Committee.
AUA guideline on management of benign prostatic hyperplasia (2003).
Chapter 1: Diagnosis and treatment recommendations.
J Urol 2003a; 170: 530-547.

AUA Practice Guidelines Committee.
AUA guideline on management of benign prostatic hyperplasia (2003).
Chapter 3: Results of the Treatment Outcomes Analyses. 2003b. www.auanet.org/timssnet/products/guidelines/main_reports/
bph_management/ chapt_3_appendix.pdf
(Recherchedatum: 08.06.2004)

Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK.
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia.
J Urol 1992; 148: 1549-1557.

Batista-Miranda JE, Diez MD, Bertran PA, Villavicencio H.
Quality-of-life assessment in patients with benign prostatic hyperplasia: effects of various interventions.
Pharmacoeconomics 2001; 19 (11): 1079-1090.

Berges R, Dreikorn K, Hofner K, Jonas U, Laval KU, Madersbacher S, Michel MC, Muschter R, Oelke M, Pientka L, Tschuschke C, Tunn U, Palmtag H, Goepel M, Schalkhäuser K, Göeckel-Beining B, Heidenreich A, Rübben H, Thon W, Thürhoff J, Weidner W.
Leitlinien der Deutschen Urologen zur Therapie des benignen Prostatasyndroms (BPS).
Urologe (A) 2003; 42 (5): 722-738.

Borboroglu PG, Kane CJ, Ward JF, Roberts JL, Sands JP.
Immediate and postoperative complications of transurethral prostatectomy in the 1990s.
J Urol 1999; 162 (4): 1307-1310.

Boyarsky S, Jones G, Paulson DF, Prout GR, Jr.
A new look at bladder neck obstruction by the food and drug administration regulators: guidelines for investigation of benign prostatic hypertrophy.
Trans Am Assoc Genitourin Surg 1976; 68: 29-32.

Fowler FJ, Jr., Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Jr., Hanley D.
Symptom status and quality of life following prostatectomy.
J Am Med Assoc 1988; 259 (20): 3018-3022.

Green JS, Bose P, Thomas DP, Thomas K, Clements R, Peeling WB, Bowsher WG.
How complete is a transurethral resection of the prostate?
Br J Urol 1996; 77 (3): 398-400.

Haab F, Yamaguchi R, Leach GE.
Postprostatectomy incontinence.
Urol Clin North Am 1996; 23 (3): 447-457.

Hakenberg OW, Helke C, Manseck A, Wirth MP.
Is there a relationship between the amount of tissue removed at transurethral resection of the prostate and clinical improvement in benign prostatic hyperplasia.
Eur Urol 2001; 39 (4): 412-417.

Hakenberg OW, Pinnock CB, Marshall VR.
Does Evaluation With the International Prostate Symptom Score Predict the Outcome of Transurethral Resection of the Prostate?
J Urol 1997; 158 (1): 94-99.

Hald T, Nordling J, Andersen JT, Bilde T, Meyhoff HH, Walter S.
A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia.
Scand J Urol Nephrol Suppl 1991; 138: 59-62.

Holtgrewe HL.
Economic issues and the management of benign prostatic hyperplasia.
Urology 1995; 46 (Supplement 3A): 23-25.

Kawamura H, Hirakawa S, Nemoto R, Miyagawa I, Matsui K.
[Prostate cancer after subcapsular prostatectomy diagnosed as benign prostate hypertrophy-clinico-pathological analysis]. Nippon Hinyokika Gakkai
Zasshi 1992; 83 (11): 1823-1827.

Kirollos MM, Campbell N.
Factors influencing blood loss in transurethral resection of the prostate (TURP): auditing TURP.
Br J Urol 1997; 80 (1): 111-115.

Levy IG, Gibbons L, Collins JP, Perkins DG, Yang M.
Prostate cancer trends in Canada: Rising incidence or increased detection?
Can Med Assoc J 1993; 149 (5): 617-624.

Madsen PO, Iversen P.
A point system for selecting operative candidates. In: Hinman F. Benigne Prostatic Hypertrophie.
New York: Springer Verlag; Kapitel 79, 763-765, 1983.

McConnell JD, Barry MJ, Bruskewitz RC.
Benign prostatic hyperplasia: diagnosis and treatment.
Agency for Health Care Policy and Research (AHCPR), 1994. 1-17.

Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC.
Transurethral prostatectomy: immediate and postoperative complications. Cooperative study of 13 participating institutions evaluating 3,885 patients.
Reprint von 1989. J Urol 2002; 167: 5-9.

Netto NR, D'Ancona CAL, de Lima M.
Correlation between the international Prostatic Symptom Score and Pressure-Flow Study in the evaluation of symptomatic Benign Prostatic Hyperpasia.
J Urol 1996; 155: 200-202.

Palmtag H, Goepel M, Berges R, Dreikorn K, Höfner K, Jonas U, Laval KU, Madersbacher S, Michel MC, Muschter R, Oelke M, Pientka L, Tschuschke C, Tunn U, Schalkhäuser K, Göeckel-Beining B, Heidenreich A, Rübben H, Thon W, Thürhoff J, Weidner W.
Leitlinien der Deutschen Urologen zur Diagnostik des benignen Prostatasyndroms (BPS).
Urologe (A) 2003; 42 (4): 584-590.

Pientka L.
Minimal-invasive Therapie der benignen Prostatahyperplasie.
HTA-Bericht 07. Köln: DIMDI; 1998.

Schulze J.
Aussagekraft des Internationalen Prostata Symptomen Score (IPSS) für Therapieplanung und Verlaufskontrolle bei der Benignen Prostatahyperplasie (BPH).
Dissertation Universität München; 2002.

Thorpe A, Neal D.
Benign prostatic hyperplasie.
Lancet 2003; 361: 1359-1367.

Vecchioli SC.
[Incidental carcinoma of the prostate. Study of 683 patients operated upon for benign prostatic hypertrophy].
Minerva Urol Nefrol 1992; 44 (2): 109-112.

Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG.
A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate.
N Engl J Med 1995; 332 (2): 75-79.

Witjes WP, de Wildt MJ, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ.
Variability of clinical and pressure-flow study variables after 6 months of watchful waiting in patients with lower urinary tract symptoms and benign prostatic enlargement.
J Urol 1996; 156 (3): 1026-1034.

Ye M, Liu F, Xie Q.
[Missed diagnosis in prostate incidental carcinoma].
Zhonghua Bing Li Xue Za Zhi 1995; 24 (6): 359-362.

Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M, Pummer K, Hubmer G.
Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients.
Urology 2003; 62: 451-455.